This methodology has often been used to study the resistance of CML to both traditional chemotherapeutics3,4, as well as BCR::ABL1 targeted TKI treatment5–16. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.